PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL: A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS